IL1B and systemic lupus erythematosus: Recently, other studies of IL-1 blockade using anakinra have shown promise in improving SLE-associated recurrent fevers, pericarditis, and macrophage activation syndrome, highlighting potential benefits for specific acute manifestations of lupus (33–36).